Healthtech
78 companies in this sector.
| # | Company | Description | Location | Status | Funding |
|---|---|---|---|---|---|
| 01 | Isomorphic Labs | London-based AI-first drug design and development company spun out of Google DeepMind in 2021. Builds the IsoDDE drug design engine leveraging AlphaFold-derived architectures to design therapeutic candidates across disease areas. CEO Demis Hassabis is also CEO of Google DeepMind. | London, United Kingdom | Private | $2.7B |
| 02 | Freenome | Biotech company developing AI-powered multiomics blood tests for early cancer detection. Its platform analyzes cell-free DNA, methylation patterns, and protein biomarkers from routine blood draws to screen for cancers in their earliest stages. Lead product SimpleScreen targets FDA approval for colorectal cancer screening. | South San Francisco, California, United States | Private | $1.3B |
| 03 | Whoop | Human performance wearable company that builds a membership-based health and fitness tracker measuring strain, recovery, and sleep. The screenless WHOOP strap provides continuous biometric monitoring, used by professional athletes and consumers globally. | Boston, United States | Private | $981M |
| 04 | Candid Therapeutics | Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager antibodies to treat autoimmune and inflammatory diseases. The company's platform redirects T-cells to selectively eliminate autoreactive B-cells, with clinical programs spanning five autoimmune indications. Founded by Ken Song after his $4.1B sale of RayzeBio to Bristol Myers Squibb. | San Diego, California, United States | Private | $875M |
| 05 | NewLimit | South San Francisco-based longevity biotech using epigenetic reprogramming (Yamanaka-style) to restore youthful cell function. Lead program targets aged human liver cells; first clinical trial planned for 2027. Co-founded 2021 by Coinbase CEO Brian Armstrong, ex-GV's Blake Byers, and computational biologist Jacob Kimmel. | South San Francisco, USA | Private | $605M |
| 06 | Cellares | South San Francisco-based first 'Integrated Development and Manufacturing Organization' (IDMO) for cell therapy. Delivered first GMP cell therapy doses to patients in April 2026. 10-year supply deal with Cabaletta Bio. Global Smart Factory network launching 2027. Founded April 2019. | South San Francisco, USA | Private | $532M |
| 07 | CellCentric | Cambridge, UK clinical-stage biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed/refractory multiple myeloma and other cancers. Based on the science of Azim Surani at the Gurdon Institute, Cambridge. | Cambridge, United Kingdom | Private | $340M |
| 08 | Verily | Precision health AI platform that helps clients streamline healthcare data and deploy actionable intelligence into research and care workflows. Spun out of Google X (Alphabet) and now operates independently after a $300M strategic investment round. | South San Francisco, United States | Private | $300M |
| 09 | Imperative Care | Commercial-stage medtech company focused on thromboembolic disease including stroke and pulmonary embolism. Products include the Zoom Stroke System, Symphony Thrombectomy System, and the Telos robotic platform for automated stroke treatment. | Campbell, United States | Private | $270M |
| 10 | Oricell Therapeutics | Chinese clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumors. Lead asset Ori-C101 targets hepatocellular carcinoma (liver cancer), aiming to become the first globally-approved CAR-T for the disease. Pipeline focused on overcoming the historical limitations of CAR-T in solid tumors. | Shanghai, China | Private | $270M |
| 11 | Iterative Health | Cambridge, Massachusetts AI-driven healthcare technology and clinical research network (originally Iterative Scopes). Started with computer vision for GI endoscopy and the SKOUT polyp detection system, now expanding into cardiology and obesity clinical trials. | Cambridge, United States | Private | $267M |
| 12 | Ray Therapeutics | Clinical-stage biotechnology company developing optogenetic gene therapies to restore vision in patients with blinding retinal diseases. Delivers bioengineered, highly light-sensitive proteins to targeted retinal cells via a single intravitreal injection. Lead program RTx-015 targets retinitis pigmentosa with FDA RMAT designation. Approach is mutation-agnostic, working across many genetic causes of blindness. | Berkeley, United States | Private | $231M |
| 13 | AKASA | AKASA is an AI-powered automation platform for healthcare revenue cycle management. Using generative AI and machine learning, it improves the efficiency, accuracy, and scalability of hospital billing and administrative operations. Founded by former Andreessen Horowitz partner Malinka Walaliyadde and Stanford PhD Varun Ganapathi, AKASA (originally named Alpha Health) serves health systems looking to reduce manual work in their billing processes. | South San Francisco, United States | Private | $205M |
| 14 | eMed | GLP-1 focused telehealth platform that partners with employers and government payers to manage GLP-1 medication usage for obesity and diabetes, building an agentic AI platform and capitated model to lower employer healthcare costs. | Miami, United States | Private | $200M |
| 15 | Tennr | New York-based AI-native patient referral and intake automation platform for healthcare providers. Auto-parses inbound faxes, EHR messages, and forms, classifies them, and routes work back into the practice management system. Founded 2021. | New York, United States | Private | $163M |
| 16 | Forus | New York AI-powered network connecting doctors, pharmacies, payers, and biopharma to automate the path from prescription to patient. Live in all 50 states. Started inside Thrive Capital's office in 2023; over $10M ARR by end-2025 and on track for $50M+ in 2026. | New York, United States | Private | $160M |
| 17 | Nourish | New York AI-powered metabolic health and virtual nutrition clinic. Dietitian-led care now pivoting to integrated physician care, lab testing, and GLP-1 prescriptions through payer partnerships. Reached $1.75B valuation on $100M Series C in May 2026. | New York, United States | Private | $153M |
| 18 | GT Medical Technologies | Tempe, Arizona-based medical device maker. Flagship GammaTile is an FDA-cleared bioresorbable radiation implant placed during brain tumor surgery. ROADS RCT data at ASCO 2026: 12-month tumor surgical bed recurrence 1.3% vs 15.4% standard of care; 24-month OS 61.7% vs 35.7%. Founded 2017 by Barrow Neurological Institute team. | Tempe, USA | Private | $153M |
| 19 | Coultreon Biopharma | Belgian immunology biotech (formerly Onco3R Therapeutics) developing COL-5671, an oral SIK3 inhibitor targeting psoriasis and ulcerative colitis. The aim is biologic-class efficacy delivered as a once-daily pill, with the lead asset transferred from Galapagos in 2025. | Leuven, Belgium | Private | $148M |
| 20 | Weave | All-in-one customer communication and payments platform for small and medium-sized healthcare businesses, serving dental, optometry, veterinary, and medical practices. | Lehi, US | Public | $146M |
| 21 | Beacon Biosignals | Combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine. Building the world's largest neurodiagnostic dataset. Making brain function measurable and actionable at scale. | Boston, United States | Private | $132M |
| 22 | Qualified Health | Public benefit corporation providing a secure enterprise AI platform for health systems. Supports 500,000+ users across health systems representing approximately 7% of U.S. hospital revenue. Customers include Mercy, Emory, Jefferson Health. | San Francisco, United States | Private | $125M |
| 23 | CREATE Medicines | Cambridge, MA clinical-stage biotech (formerly Myeloid Therapeutics) developing in vivo CAR therapies that reprogram immune cells (T cells, NK cells, myeloid cells) inside the body using an mRNA plus lipid nanoparticle delivery platform. Lead program CRT-402 targets CD19 for autoimmune disease. | Cambridge, United States | Private | $122M |
| 24 | Contraline | Charlottesville-based clinical-stage biopharma developing NES/T Gel (segesterone acetate + testosterone), a reversible male contraceptive gel. Phase 2b complete with 462 couples; Phase 3 expected 2027. Also developing the ADAM hydrogel vas deferens implant. Founded 2015. | Charlottesville, USA | Private | $110M |
| 25 | Stipple Bio | Precision oncology biotech harnessing epitope-level precision to create targeted cancer therapies. The Pointillist Platform identifies tumor-specific cell surface epitopes, enabling antibody-drug conjugates (ADCs) that avoid on-target/off-tumor toxicity. Lead candidate STP-100 expected in clinical studies early 2027. | Cambridge, United States | Private | $100M |
| 26 | Stepful | New York-based AI-powered 'school-as-a-service' training platform for allied health workers (CNA, MA, pharmacy tech). Partners with 35+ health systems including Mount Sinai, Ochsner, and Providence. 32,000+ graduates. Founded 2021. | New York, USA | Private | $99M |
| 27 | Turquoise Health | Healthcare pricing and payments platform building an operating system for healthcare contracts, using price transparency data to enable upfront pricing and real-time payment processing. | San Diego, United States | Private | $95M |
| 28 | Adonis | AI orchestration platform for healthcare revenue cycle management. Automates denial prevention, claim resolution, and revenue recovery for hospitals. 4x revenue growth in 2025 with net retention above 130%. Customers include Mount Sinai and AdventHealth. | New York, United States | Private | $95M |
| 29 | Ona Therapeutics | Barcelona-based clinical-stage biotech developing antibody-drug conjugates (ADCs) for treatment-resistant cancers. Lead programs ONA-255 (breast cancer) and ONA-389 (colorectal). Founded 2020. | Barcelona, Spain | Private | $87M |
| 30 | Latent Health | Clinical AI platform accelerating access to life-saving medications by bringing clinical intelligence directly into the patient record. Works with half of the top 20 U.S. health systems to move patients from diagnosis to therapy faster. | San Francisco, United States | Private | $80M |
| 31 | Subtle Medical | Menlo Park-based vendor-neutral AI imaging software for MRI, PET, and CT scanners. Reduces scan time up to 80%; deployed across 1,300+ scanners globally. Founded 2017 by Stanford researchers. New CEO Ohad Arazi joined alongside the Series C. | Menlo Park, USA | Private | $75M |
| 32 | Kanvas Biosciences | Princeton-based spatial biology company building a microbiome drug discovery, screening, and manufacturing platform. Lead candidate KAN-001 is a live biotherapeutic for solid-tumor patients who do not respond to immune checkpoint inhibitors. Spinout from Cornell, founded 2020. | Princeton, United States | Private | $71M |
| 33 | Courier Health | AI-powered patient experience platform purpose-built for the biopharma industry that helps life sciences manufacturers manage the end-to-end patient journey for specialty, chronic, and rare disease therapies. Integrates disparate patient data sources to create a unified view enabling personalized engagement from education and enrollment through benefits verification, therapy initiation, and ongoing adherence. Customer base grew 400% in 2025. | New York, United States | Private | $70M |
| 34 | Fluent Commerce | Global provider of distributed order management systems (OMS) that helps retailers and brands manage inventory availability and fulfillment at scale. Serves customers including Prada Group, L'Oreal, LVMH, Kingfisher, and JD Sports with cloud-native, AI-ready order management. | Sydney, AU | Private | $67M |
| 35 | Fitbit | Consumer electronics and fitness company that designed wearable activity trackers, smartwatches, and related software for tracking health metrics including steps, calories, sleep, and heart rate. | San Francisco, US | Acquired | $67M |
| 36 | Nervonik | Los Angeles-based clinical-stage medical device company developing next-generation peripheral nerve stimulation systems that integrate stimulation with real-time biomarker sensing (ECAPs). Spun out of Dr. Aydin Babakhani's UCLA Electrical and Computer Engineering lab to bring personalized neuromodulation to chronic pain. | Los Angeles, United States | Private | $66M |
| 37 | Doctronic | AI-driven healthcare platform automating medication refill approvals and prescription renewals, with 24/7 telemedicine consultations. Streamlines administrative workflows for healthcare providers and improves patient access to care. | New York, United States | Private | $65M |
| 38 | Thesis Care | AI-powered care team platform deploying AI agents backed by expert clinicians for clinical operations and care management. Formerly known as Trovo Health. | New York, United States | Private | $60M |
| 39 | Adaptive Innovations | New York and Dallas-based AI-native home-healthcare provider with around 200 clinicians, 100,000 visits in 18 months, and under 5% rehospitalization vs the 11% industry baseline. Operates across major Texas metros. Founded 2024. | New York, USA | Private | $60M |
| 40 | 9amHealth | Encinitas-based AI-driven virtual specialty care for cardiometabolic chronic conditions (obesity, diabetes, hypertension, hyperlipidemia). Partners with Fortune 100 employers and pharma to deliver chronic care management remotely. | Encinitas, United States | Private | $56M |
| 41 | NVision | Ulm-based German quantum-tech company hyperpolarizing metabolic molecules to amplify MRI signals roughly 10,000x for real-time disease metabolism imaging. Expanding into quantum computing for drug design. Backed by Abbott as Series B anchor. | Ulm, Germany | Private | $55M |
| 42 | ClearNote Health | San Diego-based blood-based early cancer detection company (formerly Camera Health). Avantect pancreatic test plus Virtuoso platform for pancreatic and ovarian cancers. Founded 2018. Operating CEO Dave Mullarkey leads commercial expansion; Kevin Keegan newly named President and COO. | San Diego, USA | Private | $52M |
| 43 | Prolium Bioscience | Clinical-stage biotech developing PRO-203, a potential best-in-class CD20xCD3 T-cell engager for severe autoimmune diseases including systemic sclerosis and lupus. | New York, New York, United States | Private | $50M |
| 44 | Clasp | Retention-driven healthcare recruitment platform that applies an ROTC-inspired model to clinical hiring. Employers commit to clinicians before graduation and repay student loans over time in exchange for tenure commitments. Delivers 2.5x higher retention rates than traditional hiring with $130M+ in employer commitments across thousands of programs. | Boston, United States | Private | $50M |
| 45 | Lassie | San Francisco-based maker of AI agents that automate medical practice administration (insurance portals, 837D claim posting, reimbursements). Started with dental: 700+ dental practices across 49 states; delivers 250,000+ labor hours annually. Founded 2024. | San Francisco, USA | Private | $47M |
| 46 | XCath | Surgical robotics company developing the Iris endovascular robotic system, the only such system in development to achieve intracranial navigation for neurointerventional treatment of brain aneurysms | Houston, United States | Private | $46M |
| 47 | ANEUVO | Developer of non-invasive neuromodulation technology for spinal cord injury rehabilitation. The ExaStim Stimulation System is a portable bioelectronic device that sends electrical pulses through a 16-channel multi-electrode array to stimulate nerves along the spinal cord. FDA Breakthrough Device Designation. CE Mark certified in 2025. | Los Angeles, United States | Private | $40M |
| 48 | DrChrono | Cloud-based medical platform offering all-in-one EHR, practice management, medical billing, and telehealth solutions. Built as the first EHR designed for iPad. Served 4,600+ independent practices and 13,000+ providers across medical specialties, managing 17.8M+ patients and $11B+ in medical billings. Apple Mobility Partner. Acquired by EverCommerce for $180M in November 2021. | Sunnyvale, United States | Acquired | $39M |
| 49 | Blossom Health | AI-native telepsychiatry platform that deploys AI copilots alongside psychiatrists. The all-in-one platform augments clinical decisions and automates back-office tasks, saving clinicians 30+ minutes per patient visit and 10+ hours per week. Serves patients through in-network virtual psychiatry. | New York, United States | Private | $38M |
| 50 | Triomics | New York-based oncology-specific AI for cancer centers. Powers clinical trial matching and chart abstraction at MSK, MD Anderson, Yale/Smilow, and Mount Sinai Tisch. Founded 2021 with operations in India. | New York, USA | Private | $37M |
| 51 | Techcyte | Orem, Utah AI-powered digital pathology platform (Fusion) serving human medical, veterinary, and environmental laboratories. Integrates AI with digitized lab workflows for diagnostic accuracy across cytology, hematology, and parasitology. | Orem, United States | Private | $36M |
| 52 | BranchLab | Boulder-based privacy-first AI platform for pharma commercialization. Identifies and activates patient and HCP audiences, runs segmentation, and measures real-world effectiveness. Delivered roughly 70% lift in client commercialization efficacy. | Boulder, United States | Private | $35M |
| 53 | Waypoint Bio | New York-based AI-native biotech using spatial pooled screening and computer vision to design in vivo CAR T therapies for solid tumors. Lead program WAY-103. Founded 2021. CTO Patrick Kaifosh previously at CTRL-Labs and Meta Reality Labs. | New York, USA | Private | $35M |
| 54 | Waiv | AI precision testing company spun out from Owkin, applying deep neural network analysis to digitized biopsy slides for oncology biomarker discovery, detection, and treatment-response prediction | Paris, France | Private | $33M |
| 55 | Advanced NanoTherapies | Santa Clara-based clinical-stage medtech company developing SirPlux Duo, the first nanoparticle-coated dual-drug (paclitaxel + sirolimus) balloon platform for coronary and peripheral artery disease. | Santa Clara, USA | Private | $31M |
| 56 | Secretome Therapeutics | Plano, Texas-based neonatal cardiac progenitor-cell (nCPC) therapy company (formerly NeoProgen). Lead asset STM-01 targets Duchenne muscular dystrophy-associated cardiomyopathy. Founded 2018. | Plano, USA | Private | $30M |
| 57 | Lucis | Paris-based AI-driven preventive healthcare platform analyzing 110+ blood biomarkers across metabolic, hormonal, cardiovascular, inflammation, and nutrient panels. 10,000+ users across France, UK, Ireland, and Portugal. Y Combinator alumnus founded 2025. | Paris, France | Private | $28M |
| 58 | Nadia Care | Community-centered maternal health platform (formerly Cayaba Care) providing hybrid virtual and in-person maternity care for Medicaid populations, with proven reductions in preterm births and NICU stays. | Washington, United States | Private | $27M |
| 59 | Ember LifeSciences | Los Angeles-based maker of reusable modular active cold-chain platforms for biopharma distribution. Launched Ember Cube 2 commercially in May 2026. Founded 2020 by Clay Alexander, also founder of consumer-temperature brand Ember. | Los Angeles, USA | Private | $27M |
| 60 | Parallel | Paris-based startup building AI agents for hospital administration. Agents operate on top of existing systems, learning to navigate them the way a human user would by reading screens, clicking interfaces, and entering data. | Paris, France | Private | $24M |
| 61 | Solstice | New York-based AI-native marketing agency for pharma. Ingests clinical data and FDA documents to cut drug-campaign timelines from 3 months to 10 days and reduce MLR review rounds from 3.2 to 1.2 on average. | New York, USA | Private | $21M |
| 62 | Signos | Palo Alto-based maker of the first FDA-cleared over-the-counter continuous glucose monitor (CGM) system for weight management. Powered by Dexcom's Stelo biosensor. Founded 2019. | Palo Alto, USA | Private | $20M |
| 63 | Coral Care | Coral Care is a pediatric therapy platform connecting families with licensed speech, occupational, and physical therapists who deliver insurance-covered services in the home. The platform supports clinicians in building flexible private practices through integrated infrastructure spanning credentialing, scheduling, documentation, and billing. | Larchmont, US | Private | $20M |
| 64 | Bellabeat | Femtech wellness company that designs fashionable health-tracking wearables and a subscription wellness service for women. Products including Leaf, Ivy, and Time track cycle, sleep, activity, stress, and reproductive health. Participated in Y Combinator W14, voted most likely to succeed by its cohort. | San Francisco, US | Private | $19M |
| 65 | Rem3dy Health | Birmingham, UK-based maker of 3D-printed personalized nutrient gummies (Nourished brand) and personalized medicine (Scripted brand). Quiz-driven, in-house 3D-printed gummy supplements via subscription. Founded 2019. | Birmingham, United Kingdom | Private | $18M |
| 66 | Aclarion | Commercial-stage healthcare technology company leveraging biomarkers and proprietary AI algorithms to help physicians identify the source of chronic low back pain. Its Nociscan platform is the first evidence-supported SaaS tool to noninvasively distinguish between painful and nonpainful discs. | Broomfield, US | Public | $17M |
| 67 | Amigo AI | Clinical AI agent platform that trains healthcare AI like doctors, enabling patient intake, triage, care navigation, and 24/7 patient support across 100+ languages with over 3 million encounters and zero safety incidents. | New York, United States | Private | $17M |
| 68 | Photon Health | New York-based AI-native digital prescription and pharmacy-routing infrastructure connecting prescribers, pharmacies, and patients with real-time price, inventory, and convenience signals at the point of e-prescribing. | New York, United States | Private | $16M |
| 69 | Rejuvenate Bio | San Diego-based gene therapy company developing longevity and age-related-disease treatments. Initial pipeline in companion animals (dogs) targeting eventual human applications. Three longevity gene targets: FGF21, sTGFβR2, αKlotho. Spinout from George Church's Harvard/Wyss Institute lab. Founded 2018. | San Diego, USA | Private | $16M |
| 70 | Perceptic | London-based AI operating system for drug discovery and clinical development covering asset scouting, scientific evaluation, indication selection, and clinical data analysis. Deployed at top-20 pharma including CSL. Founded 2024 by ex-Palantir AIP and Life Sciences leaders. | London, United Kingdom | Private | $12M |
| 71 | Veritas Aortic Solutions | Costa Mesa, California-based developer of the Transcatheter Valved Aortic Root Conduit (TVARC), a catheter-based non-surgical alternative for aortic root and ascending aortic disease. Spun out of inQB8 Medical Technologies in 2024. | Costa Mesa, USA | Private | $12M |
| 72 | Subverse | San Francisco-based AI medical coding company that processes inpatient encounters from EHR transcripts and clinical notes into compliant ICD-10 codes ready for billing. Pilots at HCA, Tenet, and Sutter Health. YC W25. Founded 2024. | San Francisco, United States | Private | $9M |
| 73 | Understood Care | AI-native patient advocacy platform for Medicare beneficiaries, combining dedicated human advocates with AI-powered automation to help patients navigate healthcare, schedule appointments, and coordinate care. | New York, United States | Private | $8M |
| 74 | Veeva Systems | Veeva Systems is a cloud computing company focused on pharmaceutical and life sciences industry applications, providing cloud-based software for customer relationship management, content management, regulatory compliance, and data management to help life sciences companies bring products to market faster. | Pleasanton, United States | Public | $7M |
| 75 | Goldenrod Therapeutics | Houston, Texas-based precision therapeutics company advancing 11h, an orally bioavailable brain-penetrant PDE4 inhibitor. First target: Friedreich's Ataxia. Then broader neurodegenerative and neuroinflammatory indications. Technology in-licensed from University of Nebraska Medical Center. Founded 2023. | Houston, USA | Private | $7M |
| 76 | Coefficient Bio | Stealth biotech AI startup using AI to accelerate drug discovery and biological research. Founded by former Genentech Prescient Design computational biology researchers. Acquired by Anthropic in April 2026 for $400M, barely 8 months after founding. Team of fewer than 10 people integrated into Anthropic's healthcare and life sciences division. | San Francisco, United States | Acquired | $5M |
| 77 | Acurion | Precision oncology technology company developing advanced diagnostic and therapeutic tools for cancer treatment. Combines AI-driven analysis with clinical workflows to enable personalized cancer care at scale. | San Diego, United States | Private | $4M |
| 78 | Procode AI | Procode AI is an AI-powered revenue cycle management company for surgeons in private practice. Its Coding Copilot enables medical coders to code 90% faster with greater accuracy by translating operative reports to billing and diagnostic codes. The company acquired The Auctus Group, the leading U.S. biller for plastic surgeons and a top-three biller in dermatology. | Los Angeles, California, United States | Private | $4M |